Zobrazeno 1 - 10
of 261
pro vyhledávání: '"Natalie S. Callander"'
Autor:
Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob Laubach, Timothy M. Schmidt, Douglas W. Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Bhagirathbhai R. Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/
Externí odkaz:
https://doaj.org/article/ebc38d6b2c3c4c4a957f6410c2bc2f56
Autor:
Rebecca W. Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Robert F. Cornell, Natalie S. Callander, Luciano J. Costa
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 775-778 (2023)
Abstract Quadruplet induction, autologous hematopoietic cell transplant (AHCT), and measurable residual disease (MRD) response‐adapted consolidation yield an unprecedented depth of response in newly diagnosed multiple myeloma. Patients treated on M
Externí odkaz:
https://doaj.org/article/49799bc37a3c41b190e485728196e1a4
Autor:
Muhamed Baljevic, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J. Bahlis, Darrell White, Christine I. Chen, Heather J. Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P. Venner, William I. Bensinger, Noa Biran, Andrew DeCastro, Dane R. Van Domelen, Chris Zhang, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Ohad S. Bentur, Brea Lipe
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1270-1276 (2022)
Abstract There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in
Externí odkaz:
https://doaj.org/article/cc625c53f2e041649d56e52c14f79586
Autor:
Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S. Callander, Alan Rapraeger, M. Suresh, Fotis Asimakopoulos, Jing Zhang
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent in advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed a VQ MM mouse model recapitulating human advanced/h
Externí odkaz:
https://doaj.org/article/ebd99a879f2644a3a391f703d60073c4
Autor:
Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, Noopur S. Raje
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 6, Pp 1-11 (2022)
Abstract A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eve
Externí odkaz:
https://doaj.org/article/0238267280cc4458be0fc24b8b97fe2d
Autor:
Muhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, Qamar Iqbal, Sibgha Gull Chaudhary, Muhammad U. Zafar, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Anurag K. Singh, Sunil H. Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAllogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for various hematologic disorders. Alternative donor strategies such as mismatched unrelated donors (MMUD) offer the option of HSCT to patients lack
Externí odkaz:
https://doaj.org/article/4182d810177847c292a0c4f1c6e1790c
Autor:
Muhammad Umair Mushtaq, Moazzam Shahzad, Amna Y. Shah, Sibgha Gull Chaudhary, Muhammad U. Zafar, Iqra Anwar, Karun Neupane, Ayesha Khalid, Nausheen Ahmed, Rajat Bansal, Ramesh Balusu, Anurag K. Singh, Sunil H. Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundNatural killer (NK) cells play a vital role in early immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT).MethodsA literature search was performed on PubMed, Cochrane, and Clinical trials.gov through Apr
Externí odkaz:
https://doaj.org/article/ec4073d4960940db9106c8740357aefa
Autor:
Andrew Kirvin-Quamme, Meredith E. Rumble, Lisa Cadmus-Bertram, Mark B. Juckett, Paul J. Rathouz, Gwynneth Schell, Natalie S. Callander, Peiman Hematti, Erin S. Costanzo
Publikováno v:
Contemporary Clinical Trials Communications, Vol 28, Iss , Pp 100938- (2022)
Background: Insomnia, fatigue, and depression are among the most persistent and distressing concerns for hematologic cancer patients recovering from hematopoietic cell transplantation (HCT). This study will evaluate a novel behavioral intervention, R
Externí odkaz:
https://doaj.org/article/d7ef9af9d496412e8b037b4766e51b34
Autor:
Sagar Lonial, Ajay K. Nooka, Praneetha Thulasi, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Heather A. Potter, Douglas Sborov, Brian E. Zaugg, Rakesh Popat, Simona Degli Esposti, Julie Byrne, Joanna Opalinska, January Baron, Trisha Piontek, Ira Gupta, Reza Dana, Asim V. Farooq, Kathryn Colby, Andrzej Jakubowiak
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
Abstract Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superfic
Externí odkaz:
https://doaj.org/article/f4fbded7918448a587750cd9f85b8f33
Autor:
Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Publikováno v:
Ophthalmology and Therapy, Vol 9, Iss 4, Pp 889-911 (2020)
Abstract Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cy
Externí odkaz:
https://doaj.org/article/c9f8e5b32350407bb7943466355dff73